CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

27.09.23		Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
05.09.23		Monthly information on share capital and company voting rights (GlobeNewswire)
07.08.23		Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)
01.08.23		Monthly information on share capital and company voting rights (GlobeNewswire)
27.07.23		Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
12.07.23		Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors (GlobeNewswire)
05.07.23		Monthly information on share capital and company voting rights (GlobeNewswire)
28.06.23		Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 (GlobeNewswire)
13.06.23		Monthly information on share capital and company voting rights (GlobeNewswire)
09.06.23		Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
05.06.23		Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire)
31.05.23		Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire)
17.05.23		Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 (GlobeNewswire)
12.05.23		Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors (GlobeNewswire)
11.05.23		Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
10.05.23		Monthly information on share capital and company voting rights (GlobeNewswire)
04.05.23		Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 (GlobeNewswire)
02.05.23		Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annua (GlobeNewswire)
27.04.23		Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
24.04.23		Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab (GlobeNewswire)
17.04.23		Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeti (GlobeNewswire)
12.04.23		Monthly information on share capital and company voting rights (GlobeNewswire)
11.04.23		Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 (GlobeNewswire)
04.04.23		Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million (GlobeNewswire)
15.03.23		Monthly information on share capital and company voting rights (GlobeNewswire)
14.03.23		Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
06.03.23		Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
01.03.23		Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 (GlobeNewswire)
09.02.23		Monthly information on share capital and company voting rights (GlobeNewswire)
10.03.20		US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis (Businesswire)
04.03.20		Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results (Businesswire)
04.03.20		Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products (Businesswire)
25.02.20		Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST (Businesswire)
18.02.20		Cellectis and Servier Expand Collaboration on UCART19 Products (Businesswire)
15.01.20		First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia (Businesswire)
06.01.20		Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery (Businesswire)
02.12.19		1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Businesswire)
20.11.19		Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells (Businesswire)
13.11.19		Cellectis Publishes Creation of "Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications (Businesswire)
06.11.19		Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 (Businesswire)
31.10.19		Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST (Businesswire)
29.10.19		First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma (Businesswire)
01.10.19		Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates (Businesswire)
06.08.19		Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 (Businesswire)
08.07.19		Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way (Businesswire)
26.06.19		Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 (Businesswire)
07.05.19		Cellectis Reports Financial Results for First Quarter 2019 (Businesswire)
02.04.19		FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients (Businesswire)
11.03.19		Cellectis Reports 4th Quarter and Full Year 2018 Financial Results (Businesswire)
07.03.19		Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

Delivery-Hero-Aktie tiefrot: Delivery-Hero-Tochter Talabat nach deutlichem Kursplus bei Börsenstart unter Ausgabepreis

Ripple fällt auf 2 US-Dollar zurück – Was passiert jetzt?

TeamViewer-Aktie in Rot: TeamViewer mit größtem Zukauf - Übernahme von 1E

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.12.2024 14:36
Kaufwert:	EUR
	Hinzufügen Speichern